Peripheral arterial occlusive disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:15:10 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Peripheral arterial occlusive disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study comparing one month versus one year of aspirin and clopidogrel treatment in patients with chronic limb-threatening ischemia after below-the-knee vascular therapy. https://clinicaltrials.eu/trial/a-study-comparing-one-month-versus-one-year-of-aspirin-and-clopidogrel-treatment-in-patients-with-chronic-limb-threatening-ischemia-after-below-the-knee-vascular-therapy/ Wed, 29 Apr 2026 15:09:17 +0000 https://clinicaltrials.eu/trial/a-study-comparing-one-month-versus-one-year-of-aspirin-and-clopidogrel-treatment-in-patients-with-chronic-limb-threatening-ischemia-after-below-the-knee-vascular-therapy/ This study focuses on patients with Chronic Limb Threatening Ischemia, a severe condition where blood flow to the legs is so poor that it causes pain or tissue damage. The research aims to determine the best length of time to use dual anti-platelet therapy, which is a combination of two medications used to prevent blood clots, following a procedure to improve blood flow in the lower legs. All participants in the study will also take rivaroxaban as part of their standard care.

Participants will be assigned to receive different treatment plans. One group will take aspirin and clopidogrel for one year, while another group will take these same medications for only one month. Some participants may receive a placebo. The study follows these individuals over a period of time to monitor health outcomes related to the leg and overall survival.

]]> A study to evaluate the efficacy and safety of orforglipron in patients with peripheral artery disease https://clinicaltrials.eu/trial/a-study-to-evaluate-the-efficacy-and-safety-of-orforglipron-in-patients-with-peripheral-artery-disease/ Wed, 29 Apr 2026 15:09:11 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-efficacy-and-safety-of-orforglipron-in-patients-with-peripheral-artery-disease/ This study is being conducted to investigate the efficacy and safety of orforglipron in individuals living with Peripheral Artery Disease. This condition involves narrowed or blocked blood vessels, which can reduce blood flow to the limbs. The study compares the effects of the experimental tablet against a placebo.

Participants will be assigned to different groups to receive either orforglipron or a placebo once daily by oral use. During the study, the ability to walk a certain distance will be monitored to see how the medication affects movement and physical activity over time.

]]> Study of APAC (antiplatelet, anticoagulant) treatment in patients with peripheral arterial disease and chronic limb-threatening ischemia during blood vessel restoration procedure https://clinicaltrials.eu/trial/study-of-apac-antithrombotic-treatment-for-patients-with-peripheral-arterial-occlusive-disease-and-chronic-limb-threatening-ischemia-during-blood-vessel-repair/ Wed, 29 Apr 2026 15:06:20 +0000 https://clinicaltrials.eu/trial/study-of-apac-antithrombotic-treatment-for-patients-with-peripheral-arterial-occlusive-disease-and-chronic-limb-threatening-ischemia-during-blood-vessel-repair/ This clinical trial focuses on patients with Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia, conditions that cause reduced blood flow to the legs. The study tests a new medication called APAC, which combines properties of blood thinning and anti-clotting medicines. The treatment is given through intravenous administration, meaning it is delivered directly into the bloodstream.

The study aims to evaluate how safe and well-tolerated APAC is when given to patients, particularly those undergoing procedures to restore blood flow to their legs. During the study, some patients will receive APAC as a single dose, while others will receive weekly doses. The medication will be used alongside standard blood-thinning medicines such as acetylsalicylic acid or clopidogrel. Sodium chloride solution and heparin will also be used during the treatment.

Throughout the study, patients will undergo various health checks including physical examinations, blood tests, and measurements of blood flow in their legs. The study will monitor how well patients can walk and assess their quality of life. Doctors will also check for any side effects, particularly focusing on any bleeding events that might occur during the treatment period.

]]> Study on the Effects of TRI-001 for Patients with Chronic Limb Threatening Ischemia Due to Peripheral Arterial Disease https://clinicaltrials.eu/trial/study-on-the-effects-of-tri-001-for-patients-with-chronic-limb-threatening-ischemia-due-to-peripheral-arterial-disease/ Wed, 29 Apr 2026 15:04:24 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-tri-001-for-patients-with-chronic-limb-threatening-ischemia-due-to-peripheral-arterial-disease/ This clinical trial is focused on studying a condition called Chronic Limb Threatening Ischemia (CLTI), which occurs due to Peripheral Arterial Disease (PAD). This condition affects blood flow to the limbs, often leading to severe pain and wounds that do not heal properly. The study is testing a new treatment called TRI-001, which is a type of cell therapy involving allogeneic regulatory macrophages. These are special cells that may help improve healing and blood flow in affected limbs. The treatment is given as a single injection into the muscle.

The purpose of the study is to evaluate the safety and effectiveness of TRI-001 in patients with this condition. Participants will receive either the new treatment or a placebo, which is an inactive substance. The study will monitor the size of the wounds and any changes in the condition over time. The trial will also assess how well patients tolerate the treatment and any side effects that may occur.

Throughout the study, participants will have regular check-ups to monitor their health and the progress of their condition. The study aims to see if TRI-001 can help reduce the size of wounds and improve the quality of life for those with Chronic Limb Threatening Ischemia. The trial will last for several months, with the main results expected to be available by 2027.

]]> Study on the Safety of Leukocyte-Platelet Rich Fibrin for Patients with Critical Limb Ischemia https://clinicaltrials.eu/trial/study-on-the-safety-of-leukocyte-platelet-rich-fibrin-for-patients-with-critical-limb-ischemia/ Wed, 29 Apr 2026 15:04:05 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-leukocyte-platelet-rich-fibrin-for-patients-with-critical-limb-ischemia/ This clinical trial is focused on studying a condition known as critical limb ischemia, which is a severe blockage in the arteries of the lower limbs that significantly reduces blood flow. The study will explore the use of a treatment called Leukocyte-Platelet Rich Fibrin (L-PRF). This treatment involves using a special suspension made from a protein called fibrin, which is introduced into the body through an injection into the muscle.

The main purpose of the study is to assess the safety of using L-PRF in treating critical limb ischemia. Participants in the study will receive either the L-PRF treatment or a placebo. The study will monitor participants over a period to observe any reactions or events that occur during the treatment and at the final visit. The study will also look at various outcomes, such as the rate of survival without amputation, the time it takes for blood flow to improve, and changes in quality of life.

Throughout the study, participants will undergo regular assessments to track their progress. These assessments will include imaging studies to check muscle blood flow, measurements of blood pressure in the limbs, and evaluations of any changes in the severity of their condition. The study aims to provide valuable information on the potential benefits and safety of using L-PRF for patients with critical limb ischemia.

]]> Study on the Effects of Autologous Bone Marrow-Derived Mononuclear Cells for Patients with Diabetic Foot Syndrome and Lower Limb Ischemia https://clinicaltrials.eu/trial/study-on-the-effects-of-autologous-bone-marrow-derived-mononuclear-cells-for-patients-with-diabetic-foot-syndrome-and-lower-limb-ischemia/ Wed, 29 Apr 2026 15:03:48 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-autologous-bone-marrow-derived-mononuclear-cells-for-patients-with-diabetic-foot-syndrome-and-lower-limb-ischemia/ This clinical trial is focused on studying the effects of a new treatment for patients with chronic limb-threatening ischemia and diabetic foot ulcers. These conditions are serious complications often seen in people with diabetes, where there is poor blood flow to the lower limbs, leading to severe pain and ulcers that are difficult to heal. The treatment being tested involves using a special type of cell therapy called autologous bone marrow-derived mononuclear cells, also known by the code name REX-001. These cells are taken from the patient’s own bone marrow and are injected back into the body to help improve blood flow and promote healing.

The purpose of the study is to compare the effects of this cell therapy with the standard treatment currently available for these conditions. Participants in the study will receive either the cell therapy or the standard treatment, and their progress will be monitored over time. The study aims to see if the cell therapy can improve tissue oxygenation, which is the amount of oxygen reaching the tissues, and lead to better healing of the ulcers, less pain, and a lower risk of needing major amputations.

Throughout the study, researchers will also look at the safety of the cell therapy by monitoring any side effects that occur. Participants will be asked to provide feedback on their experience with the treatment through questionnaires. The study will also explore how the quality of the cell suspension used in the therapy relates to improvements in blood flow and healing. The trial is expected to continue until the end of 2027, providing valuable insights into the potential benefits of this innovative treatment approach for patients with these challenging conditions.

]]> Study on Bone Marrow Cells and Saline for Treating Severe Limb Ischemia in Patients at High Risk of Amputation https://clinicaltrials.eu/trial/study-on-bone-marrow-cells-and-saline-for-treating-severe-limb-ischemia-in-patients-at-high-risk-of-amputation/ Wed, 29 Apr 2026 15:03:18 +0000 https://clinicaltrials.eu/trial/study-on-bone-marrow-cells-and-saline-for-treating-severe-limb-ischemia-in-patients-at-high-risk-of-amputation/ This clinical trial is focused on studying a condition known as chronic limb ischemia, which is a severe blockage in the arteries of the lower extremities that significantly reduces blood flow. This condition can lead to pain and increase the risk of amputation. The study is particularly concerned with patients who are at high risk of losing a limb due to this condition. The treatment being tested involves using autologous bone marrow-derived cells, which are cells taken from the patient’s own bone marrow, to see if they can help improve blood flow and reduce the risk of amputation.

The purpose of the study is to evaluate the safety and effectiveness of this treatment. Researchers aim to see if the treatment can decrease pain, improve the function of the affected limb, and delay or prevent amputation. The study will also explore the best way to administer the treatment. Participants will receive the treatment through an injection directly into the artery, and the effects will be monitored over time to assess any changes in their condition.

Throughout the study, participants will be observed for any side effects and improvements in their condition. The goal is to determine if this new approach can offer a viable option for those who have no other surgical or medical options available. The study will help to understand if using the patient’s own cells can promote healing and improve quality of life for individuals with severe chronic limb ischemia.

]]> Study on Low-Dose Colchicine for Patients with Peripheral Artery Disease to Reduce Cardiovascular Risks https://clinicaltrials.eu/trial/study-on-low-dose-colchicine-for-patients-with-peripheral-artery-disease-to-reduce-cardiovascular-risks/ Wed, 29 Apr 2026 15:03:16 +0000 https://clinicaltrials.eu/trial/study-on-low-dose-colchicine-for-patients-with-peripheral-artery-disease-to-reduce-cardiovascular-risks/ This clinical trial is focused on studying the effects of a medication called Colchicine in patients with Peripheral Artery Disease (PAD). Peripheral Artery Disease is a condition where the blood vessels outside the heart and brain become narrowed, often leading to reduced blood flow to the limbs. The study will use Colchicine Tiofarma 500 microgram Tablets, which is a low-dose form of the medication, to see if it can help reduce the risk of serious heart and blood vessel problems in people with this condition.

The purpose of the study is to examine how effective and safe Colchicine is in lowering the chances of events like heart attacks, strokes, or severe issues with blood flow to the limbs that might require medical procedures or even amputation. Participants in the study will either receive the Colchicine tablets or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for a period of time, during which participants will take the tablets daily and be monitored for any changes in their health.

Throughout the study, researchers will keep track of various health outcomes, such as the occurrence of heart-related events, hospitalizations, and any need for medical procedures to improve blood flow. The goal is to determine if taking Colchicine can help improve the quality of life and reduce the risk of serious complications for people living with Peripheral Artery Disease.

]]> Study on the Effectiveness of Autologous Bone Marrow-Derived Mononuclear Cells and Angioplasty in Diabetic Patients with Chronic Limb-Threatening Ischemia https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-autologous-bone-marrow-derived-mononuclear-cells-and-angioplasty-in-diabetic-patients-with-chronic-limb-threatening-ischemia/ Wed, 29 Apr 2026 15:02:58 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-autologous-bone-marrow-derived-mononuclear-cells-and-angioplasty-in-diabetic-patients-with-chronic-limb-threatening-ischemia/ This clinical trial is focused on studying the effects of a new treatment for people with chronic limb-threatening ischemia and diabetic foot ulcers. These conditions are serious complications often seen in individuals with diabetes, where there is poor blood flow to the legs and feet, leading to severe pain and ulcers that are difficult to heal. The treatment being tested involves a combination of autologous cell therapy and a procedure called percutaneous transluminal angioplasty (PTA). Autologous cell therapy uses a patient’s own cells, specifically autologous bone marrow-derived mononuclear cells, which are injected into the body to help improve blood flow and healing. This cell therapy is also known by the code names REXMYELOCEL-T or REX-001.

The purpose of the study is to compare the effectiveness of this combined treatment with the standard treatment of PTA alone. Participants in the study will receive either the combination of cell therapy and PTA or just PTA. The study will monitor the rate of major amputations, the healing of wounds, and the oxygen levels in the tissues of the affected limbs. These factors will help determine how well the treatments are working. The study will also look at other aspects such as pain levels, overall quality of life, and any side effects that may occur.

Throughout the study, participants will undergo regular check-ups and assessments to track their progress. The study aims to provide valuable information on whether the addition of autologous cell therapy can improve outcomes for patients with these challenging conditions. The trial is expected to continue for several years to gather comprehensive data on the long-term effects and safety of the treatments being tested.

]]> Study on Genotype-Guided Treatment with Carbasalate Calcium, Telmisartan, and Rivaroxaban for Patients with Peripheral Arterial Disease https://clinicaltrials.eu/trial/study-on-genotype-guided-treatment-with-carbasalate-calcium-telmisartan-and-rivaroxaban-for-patients-with-peripheral-arterial-disease/ Wed, 29 Apr 2026 15:02:27 +0000 https://clinicaltrials.eu/trial/study-on-genotype-guided-treatment-with-carbasalate-calcium-telmisartan-and-rivaroxaban-for-patients-with-peripheral-arterial-disease/ This clinical trial is focused on studying treatments for Peripheral Arterial Disease (PAD), a condition where the blood vessels in the legs are narrowed, reducing blood flow and causing symptoms like pain or cramping. The study is comparing a new approach to treatment that uses genetic information to guide therapy, against the standard treatment with Clopidogrel, a medication that helps prevent blood clots. The new approach involves using different medications, including Carbasalate Calcium and Rivaroxaban, which are designed to prevent blood clots in different ways.

The purpose of the study is to see if the new, personalized treatment strategy can better reduce the risk of serious health problems related to blood clots, such as heart attacks, strokes, or issues with blood flow to the limbs, compared to the usual treatment. Participants in the study will receive either the standard treatment or the new treatment based on their genetic makeup, and their health will be monitored over a period of time to track any major health events.

The study will last for up to 36 months, during which participants will take their assigned medication and have regular check-ups to monitor their health. The main goal is to determine if the new treatment approach can lower the chances of serious complications from PAD, including major cardiovascular events, limb problems, or death, compared to the conventional use of Clopidogrel.

]]> Study of sildenafil to improve walking distance in patients with peripheral arterial disease and intermittent claudication https://clinicaltrials.eu/trial/study-on-sildenafil-for-improving-walking-distance-in-patients-with-peripheral-arterial-disease-and-intermittent-claudication/ Wed, 29 Apr 2026 14:58:47 +0000 https://clinicaltrials.eu/trial/study-on-sildenafil-for-improving-walking-distance-in-patients-with-peripheral-arterial-disease-and-intermittent-claudication/ This study focuses on Peripheral Arterial Disease, a condition where blood flow to the legs is reduced, causing pain while walking (known as intermittent claudication). The study will test whether sildenafil citrate can help patients walk longer distances compared to placebo. This medication will be taken orally as tablets for a period of 24 weeks.

The main goal is to determine if sildenafil can improve walking ability in people who experience leg pain that limits their walking distance. Participants will use a treadmill to measure how far they can walk before being stopped by leg pain. The study will track changes in walking distance over time and monitor other aspects of vascular health.

During the study, participants will take either sildenafil or placebo tablets daily. The maximum daily dose of sildenafil will be 140 mg. Throughout the study period, various measurements will be taken to assess walking ability, blood vessel function, and overall health status. The total duration of follow-up will be 48 weeks to evaluate the long-term effects of the treatment.

]]> Study on Etrinabdione for Patients with Peripheral Arterial Disease: Evaluating Safety and Tolerability https://clinicaltrials.eu/trial/study-on-etrinabdione-for-patients-with-peripheral-arterial-disease-evaluating-safety-and-tolerability/ Wed, 29 Apr 2026 14:29:30 +0000 https://clinicaltrials.eu/trial/study-on-etrinabdione-for-patients-with-peripheral-arterial-disease-evaluating-safety-and-tolerability/ This clinical trial is focused on studying a condition known as Peripheral Arterial Disease (PAD), which affects blood circulation in the legs. The trial will test a new medication called Etrinabdione, also known by its code names EHP-101 and VCE-004.8. Etrinabdione is provided as an oral solution, meaning it is taken by mouth in liquid form. The purpose of the study is to evaluate the safety and tolerability of Etrinabdione in patients with PAD.

Participants in the study will receive Etrinabdione for up to 12 months. Throughout the study, researchers will monitor the incidence and severity of any treatment-related side effects. Additionally, they will observe changes in various health indicators, such as blood flow in the legs, using methods like Angio-CT and Doppler ultrasound. The study will also assess improvements in quality of life and measure levels of Etrinabdione in the blood at different times.

The trial aims to gather preliminary information on how well Etrinabdione works in improving symptoms of PAD, such as leg pain during walking, known as claudication. By the end of the study, researchers hope to better understand the potential benefits and risks of using Etrinabdione for treating PAD.

]]> Study on Montelukast for Patients with Peripheral Artery Disease Undergoing Endovascular Treatment https://clinicaltrials.eu/trial/study-on-montelukast-for-patients-with-peripheral-artery-disease-undergoing-endovascular-treatment/ Wed, 29 Apr 2026 14:27:50 +0000 https://clinicaltrials.eu/trial/study-on-montelukast-for-patients-with-peripheral-artery-disease-undergoing-endovascular-treatment/ This clinical trial is focused on studying the effects of a medication called montelukast on patients with peripheral artery disease, a condition where the arteries in the legs become narrowed or blocked, leading to reduced blood flow. The study aims to understand how montelukast, which is a type of medication known as a cysteinyl leukotriene receptor antagonist, can help prevent the re-narrowing of arteries after they have been treated with a procedure called endovascular treatment. This procedure is used to open up blocked arteries and improve blood flow in the legs.

Participants in the study will receive either montelukast or a placebo. The study will observe the effects of the medication over a period of time to see if it helps in reducing the rate of artery re-narrowing, also known as restenosis. The study will also look at other outcomes such as major adverse cardiovascular events (MACE), the need for high lower limb amputation, and changes in the quality of life of the participants.

The purpose of this study is to explore the potential benefits of using montelukast in patients who have undergone endovascular treatment for peripheral artery disease. By understanding its effects, researchers hope to find better ways to manage this condition and improve the health and well-being of patients affected by it.

]]> Study on BGC101 for Treating Peripheral Arterial Disease with Critical Limb Ischemia in Patients Not Responding to Standard Treatments https://clinicaltrials.eu/trial/study-on-bgc101-for-treating-peripheral-arterial-disease-with-critical-limb-ischemia-in-patients-not-responding-to-standard-treatments/ Wed, 29 Apr 2026 14:23:02 +0000 https://clinicaltrials.eu/trial/study-on-bgc101-for-treating-peripheral-arterial-disease-with-critical-limb-ischemia-in-patients-not-responding-to-standard-treatments/ This clinical trial is focused on studying a condition known as peripheral arterial disease (PAD), specifically in patients with a severe form called critical limb ischemia (CLI). This condition affects blood flow to the limbs, often leading to pain and potential limb loss. The study is testing a new treatment called BGC101, which is a type of cell therapy. This treatment involves using special cells derived from the patient’s own blood, including endothelial progenitor cells, haematopoietic stem/progenitor cells, activated dendritic cells, and T helper cells. These cells are prepared as a suspension for injection and are administered through an intramuscular injection.

The purpose of the study is to evaluate how feasible, safe, and effective BGC101 is for patients with PAD and CLI who have not responded to standard treatments and do not have the option for further surgical procedures to restore blood flow. The study will be conducted in two phases, with some participants receiving the actual treatment and others receiving a placebo. Participants will be monitored for any side effects and the overall health of their limbs over the course of the study.

Throughout the study, researchers will assess the safety of BGC101 by observing any adverse events, changes in vital signs, and reactions at the injection site. They will also evaluate the treatment’s effectiveness by measuring the rate of major amputations and the survival of limbs without amputation over a 12-month period. This study aims to provide new insights into treating PAD with CLI, offering hope for patients who have limited treatment options.

]]> Study on Preventing Kidney Problems in Peripheral Arterial Disease Patients Using Carbon Dioxide and Iopamidol, Iomeprol, and Iopromide During Vascular Procedures https://clinicaltrials.eu/trial/study-on-preventing-kidney-problems-in-peripheral-arterial-disease-patients-using-carbon-dioxide-and-iopamidol-iomeprol-and-iopromide-during-vascular-procedures/ Wed, 29 Apr 2026 14:22:40 +0000 https://clinicaltrials.eu/trial/study-on-preventing-kidney-problems-in-peripheral-arterial-disease-patients-using-carbon-dioxide-and-iopamidol-iomeprol-and-iopromide-during-vascular-procedures/ This clinical trial is focused on studying a condition known as Peripheral Arterial Disease (PAD), which affects blood flow in the arteries outside of the heart and brain, often in the legs. The study is exploring a new approach to reduce the risk of kidney problems that can occur after certain medical procedures. This approach involves using a special gas called Carbon Dioxide (CO2) instead of traditional iodinated contrast during procedures to open up blocked arteries in the legs. The goal is to see if this method can help prevent serious kidney issues, known as Major Adverse Kidney Events (MAKE), in patients who are at a higher risk of kidney damage from these procedures.

The trial will include several different types of contrast solutions, such as Solutrast, Imeron, Ultravist, VISIPAQUE, ACCUPAQUE, and Optiray, which are used to improve the visibility of blood vessels during imaging tests. These solutions contain substances like iopamidol, iomeprol, iopromide, iodixanol, iohexol, and ioversol. The study will compare the effects of using these traditional contrast solutions with the new CO2 method to determine which is more effective in preventing kidney problems.

Participants in the study will undergo a procedure called infrainguinal peripheral vascular intervention (PVI), which is a treatment for blocked arteries in the legs. The study will monitor the participants for up to 90 days after the procedure to assess the occurrence of kidney-related issues. The aim is to find out if the CO2 method can reduce the risk of kidney damage compared to the use of traditional contrast solutions. This research is important for improving the safety of medical procedures for patients with PAD who are at risk of kidney problems.

]]>